Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.

IF 5.7 2区医学 Q1 RHEUMATOLOGY

Current Rheumatology Reports Pub Date : 2024-05-01 Epub Date: 2024-02-19 DOI:10.1007/s11926-024-01139-8

Wang-Chun Ho, Chung-Chih Chang, Wen-Tien Wu, Ru-Ping Lee, Ting-Kuo Yao, Cheng-Huan Peng, Kuang-Ting Yeh

{"title":"Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.","authors":"Wang-Chun Ho, Chung-Chih Chang, Wen-Tien Wu, Ru-Ping Lee, Ting-Kuo Yao, Cheng-Huan Peng, Kuang-Ting Yeh","doi":"10.1007/s11926-024-01139-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: The purpose of this literature review was to determine if medications used to treat osteoporosis are also effective for treating osteoarthritis (OA).Recent findings: A total of 40 relevant articles were identified. Studies were categorized into those (1) discussing estrogen and selective estrogen receptor modulators (SERMs), (2) bisphosphonates, (3) parathyroid hormone (PTH) analogs, and (4) denosumab, and (5) prior review articles. A large amount of evidence suggests that estrogen and SERMs are effective at reducing OA symptoms and disease progression. Evidence suggests that bisphosphonates, the most common medications used to treat osteoporosis, can reduce OA symptoms and disease progression. In vivo studies suggest that PTH analogs may improve the cartilage destruction associated with OA; however, few human trials have examined its use for OA. Denosumab is approved to treat osteoporosis, bone metastases, and certain types of breast cancer, but little study has been done with respect to its effect on OA. The current evidence indicates that medications used to treat osteoporosis are also effective for treating OA. Estrogen, SERMs, and bisphosphonates have the most potential as OA therapies. Less is known regarding the effectiveness of PTH analogs and denosumab in OA, and more research is needed.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11063098/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-024-01139-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The purpose of this literature review was to determine if medications used to treat osteoporosis are also effective for treating osteoarthritis (OA).

Recent findings: A total of 40 relevant articles were identified. Studies were categorized into those (1) discussing estrogen and selective estrogen receptor modulators (SERMs), (2) bisphosphonates, (3) parathyroid hormone (PTH) analogs, and (4) denosumab, and (5) prior review articles. A large amount of evidence suggests that estrogen and SERMs are effective at reducing OA symptoms and disease progression. Evidence suggests that bisphosphonates, the most common medications used to treat osteoporosis, can reduce OA symptoms and disease progression. In vivo studies suggest that PTH analogs may improve the cartilage destruction associated with OA; however, few human trials have examined its use for OA. Denosumab is approved to treat osteoporosis, bone metastases, and certain types of breast cancer, but little study has been done with respect to its effect on OA. The current evidence indicates that medications used to treat osteoporosis are also effective for treating OA. Estrogen, SERMs, and bisphosphonates have the most potential as OA therapies. Less is known regarding the effectiveness of PTH analogs and denosumab in OA, and more research is needed.

查看原文本刊更多论文

骨质疏松症治疗对绝经后妇女骨关节炎进展的影响：文献综述。

综述目的：本文献综述旨在确定用于治疗骨质疏松症的药物是否也能有效治疗骨关节炎（OA）：共找到 40 篇相关文章。研究分为以下几类：（1）讨论雌激素和选择性雌激素受体调节剂（SERMs）的研究；（2）讨论双膦酸盐的研究；（3）讨论甲状旁腺激素（PTH）类似物的研究；（4）讨论地诺单抗的研究；（5）讨论以前的综述文章的研究。大量证据表明，雌激素和 SERMs 能有效减轻 OA 症状和疾病进展。有证据表明，治疗骨质疏松症最常用的药物双膦酸盐可减轻 OA 症状和疾病进展。体内研究表明，PTH 类似物可改善与 OA 相关的软骨破坏；但很少有人体试验对其在 OA 中的应用进行研究。地诺单抗（Denosumab）被批准用于治疗骨质疏松症、骨转移和某些类型的乳腺癌，但有关其对 OA 影响的研究却很少。目前的证据表明，用于治疗骨质疏松症的药物也能有效治疗 OA。雌激素、SERMs 和双膦酸盐最有可能作为 OA 治疗药物。至于 PTH 类似物和地诺单抗对 OA 的疗效，目前所知较少，需要进行更多的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.